Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for HIV nerve pain: Drug-Free relief on the horizon?

NCT ID NCT03855111

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested new non-drug treatments to reduce nerve pain in the feet and legs of people with HIV. 161 adults with HIV-related nerve pain tried these approaches to see if they could ease pain and improve quality of life. The goal was to find better ways to manage this common, painful condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

161 people

The number who actually took part.

Started

Jan 2019

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women, 18 years of age or older, HIV+ or AIDS diagnosed, with a history of DSP of the lower extremities for the past three months or greater. * Primary care provider (PCP) verification of HIV status, diagnosis of DSP, \& subject clinical suitability for the study. * Evidence of lower limb neuropathy (bilateral ankle reflexes absent or depressed relative to the knee, decreased sensation to vibration, pin prick and temperature with distal sensory loss grading to normal in the proximal limb) * GPS rated pain severity of "moderate" or above, documented in 1-week prospective self-report symptom diary (SD). * Any antiretroviral Rx must have 3 months of stable regimen (same drugs, dose \& frequency) prior to enrollment. * Any pain medications must have 3 months of stable regimen prior to enrollment. * Those on a stable pharmacologic regimen are expected to remain on the regimen for the duration of the study. * Must understand and agree to complete daily symptom diaries for the duration of the study. * Successfully complete a mini-mental status exam (obtaining a score of 24 or above). Exclusion Criteria: * Any acute condition requiring medical care (eg. opportunistic infection). * Conditions that may mimic HIV DSP symptoms: i.e. diabetes(3), coagulopathies, B12 deficiency, etc. * Use any topically applied medications to the lower extremities. * Alcohol and/or substance dependence. * Use of injectable corticosteroids or any medications known to be neurotoxic within 3 months prior to enrollment. * Pregnant women or unwilling to use an acceptable form of birth control. * Receiving acupuncture within 6 months prior to enrollment. * Any history of receiving moxibustion. * Currently receiving any other complementary therapies such as herbs, massage, reiki etc. * Relocation or plans that interfere with attending all of the planned study sessions and/or recording SD information.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV distal sensory peripheral neuropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • New York University, Division of Special Studies in Symptom Management

    New York, New York, 10010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.